Normal view MARC view ISBD view

Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials

In Clinical Oncology
Contributor(s): thomas.hogberg@med.lu.se | Hogberg T.
Material type: materialTypeLabelArticleSeries: Vol 20 Issues 6.Publisher: 2008Description: 463-469.Subject(s): micrometastatic | endometrial | chemotherapy | Adjuvant | DDC classification: In: Clinical OncologySummary: Endometrial cancer generally has a good prognosis because most cases are diagnosed in stage I. It is possible to identify subgroups of patients with early stage endometrial cancer with a poor prognosis. Despite a traditional generous use of adjuvant radiotherapy those patients have less than an 80% 5-year overall survival. In this group there is a need for an effective systemic adjuvant therapy. Two randomised studies have shown better response rates but no significant difference in overall survival for doxorubicincisplatin vs doxorubicin in advanced or recurrent endometrial cancer. Mainly on the basis of the superior response rates, doxorubicincisplatin was for many years regarded as the standard chemotherapy in endometrial cancer. GOG-177 was the first phase III study on chemotherapy in advanced or recurrent endometrial cancer that showed a survival advantage. Paclitaxeldoxorubicincisplatin was better than doxorubicincisplatin, but the toxicity of the three-drug regimen has precluded general acceptan
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
(Browse shelf) Available AR9018

Endometrial cancer generally has a good prognosis because most cases are diagnosed in stage I. It is possible to identify subgroups of patients with early stage endometrial cancer with a poor prognosis. Despite a traditional generous use of adjuvant radiotherapy those patients have less than an 80% 5-year overall survival. In this group there is a need for an effective systemic adjuvant therapy. Two randomised studies have shown better response rates but no significant difference in overall survival for doxorubicincisplatin vs doxorubicin in advanced or recurrent endometrial cancer. Mainly on the basis of the superior response rates, doxorubicincisplatin was for many years regarded as the standard chemotherapy in endometrial cancer. GOG-177 was the first phase III study on chemotherapy in advanced or recurrent endometrial cancer that showed a survival advantage. Paclitaxeldoxorubicincisplatin was better than doxorubicincisplatin, but the toxicity of the three-drug regimen has precluded general acceptan

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha